Gene therapy, a revolutionary approach to treating and preventing diseases by modifying faulty genes, relies heavily on accurate measurement techniques. Ensuring the safety and efficacy of these treatments necessitates precise quantification of adeno-associated virus (AAV) vectors, which deliver
Imagine a world where getting vaccinated no longer means facing a needle and syringe, but instead, involves a simple patch applied to the skin. This prospect is rapidly becoming a reality thanks to the innovative work of the University of Queensland (UQ) and Brisbane-based biotech company Vaxxas.
Glioblastoma multiforme, an aggressive form of brain cancer, has long been a formidable challenge in the medical field. With patient survival rates stagnating around 15 to 18 months, the need for innovative treatment approaches is critical. NeOnc Technologies, under the leadership of Dr. Thomas
Adicet Bio is pioneering significant developments in its innovative CAR T-cell therapy, ADI-001, aimed at treating a range of autoimmune diseases. Among the targeted conditions are ANCA-associated vasculitis (AAV), systemic lupus erythematosus (SLE), and systemic sclerosis. Initially, patient
The contract development and manufacturing organization (CDMO) industry has seen significant advancements and partnerships as of January 2025. With a focus on large molecules and advanced therapies, this article delves into the latest developments, highlighting key trends, common themes, and
Aspect Biosystems, a pioneer in the field of bioprinted tissue therapeutics, recently closed a $115 million Series B financing round aimed at advancing its groundbreaking technology in regenerative medicine. This achievement, led by Dimension and supported by investors such as Novo Nordisk and
